Data from the Glow trial of Gelesis’s obesity therapeutic Gelesis100 looked mediocre when they were toplined more than a year ago; publication of the full dataset has not yielded anything more impressive. The product is a pill containing a cellulose-based hydrogel which expands in the stomach, occupying around a quarter of the volume. The trial hit one of its endpoints, with 59% of Gelesis100-treated adults achieving weight loss of at least 5% at six months, vs 42% in the placebo group. The other endpoint, placebo-adjusted weight loss super-superiority with a margin of 3%, was not met; the weight loss came in at 2.1%. The equivalent weight loss figures for other, approved, obesity devices range from 3.2% to 18%, though to be fair their administration can be more onerous. The average excess weight loss with Gelesis100 was 29%, again not hugely impressive versus its rivals. Gelesis has pointed to a “super-responder” group, which it says made up 27% of the Gelesis100 ITT population, who lost at least 10% of their bodyweight – but by that definition, 15% of the control group were super-responders to placebo. Gelesis, an affiliate of Puretech Health, has filed Gelesis100 with the FDA.